Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.57 |
| ▸ | HTR2A | P28223 | 10/20 | 0.57 |
| ▸ | HTR2B | P41595 | 10/20 | 0.57 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23944932 | 0.82 | PARP1 (0.46) | PNMTPARP1 | |
| SCHEMBL1278375 | 0.76 | BCL2L1 (0.52) | PARP1 | |
| SCHEMBL15502922 | 0.76 | HTR2C (0.50) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL4507795 | 0.76 | NOTUM (0.47) | HTR2CHTR2AHTR2BPNMTPARP1 | |
| SCHEMBL9461283 | 0.73 | BCL2L1 (0.50) | PARP1 | |
| SCHEMBL2534784 | 0.73 | PNMT (0.55) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL12579957 | 0.73 | HTR2C (0.62) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL10199923 | 0.73 | HTR2C (0.62) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL15821044 | 0.72 | HTR2C (0.44) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL15819018 | 0.71 | HTR2C (0.47) | HTR2CHTR2AHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938345-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT Holding Company (US) | 2015-11-04 | — | — | EP | claimed |
| US-20140275035-A1 | THIENYLINDOLE AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-09-18 | — | — | US | claimed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | claimed |
| WO-2014100815-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-06-26 | — | — | WO | claimed |
| EP-2938345-B1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9309262-B2 | Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2938345-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT Holding Company (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014159067-A1 | THIENYLINDOLE AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275035-A1 | THIENYLINDOLE AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014100815-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100815-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-1343796-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1343796-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002034760-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275035-A1 | THIENYLINDOLE AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 11/4885 |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.